Dr. Robert Y. Lin, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Medical school
- State University of Ny Upstate Medical University (1976)
- Years since graduation
- 50
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 66
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1976Medical school: State University of Ny Upstate Medical University
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
NY license 131322-1 -
Allergy & Immunology (Internal Medicine) Physician
NY license 131322-1 -
Clinical & Laboratory Immunology (Allergy & Immunology) Physician
NY license 131322-1
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 66
- Services billed
- 531
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 460 | 14 |
| Professional service for multiple injections of allergen | 112 | 24 |
| Test for allergy using combination of methods with drug or biological | 51 | 12 |
| Established patient office or other outpatient visit, 20-29 minutes | 47 | 31 |
| New patient office or other outpatient visit, 45-59 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azelastine Hcl Other prescribers in New York, NY | 289 |
| Fluticasone Propionate Other prescribers in New York, NY | 219 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in New York, NY | 119 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in New York, NY | 71 |
| Montelukast Sodium Other prescribers in New York, NY | 64 |
| Xolair (omalizumab) | 55 |
| Famotidine Other prescribers in New York, NY | 54 |
| Dupixent Pen (dupilumab) Other prescribers in New York, NY | 49 |
| Levocetirizine Dihydrochloride Other prescribers in New York, NY | 44 |
| Triamcinolone Acetonide Other prescribers in New York, NY | 39 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 146 payments worth $4,105 in total to this clinician.
| Food and Beverage | $4,105 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $5,093 in research payments for these studies, mostly to the institutions running them.
- Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT03428646 - Registry of Asthma Patients Initiating DUPIXENT®
Regeneron Pharmaceuticals, Inc. · Completed · NCT04287621
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.